The feasibility study of Dose-Dense chemotherapy for operable Japanese breast cancer patients(SBP 09) Background: Dose-dense(D-D) chemotherapy for operable breast cancer revealed significant survival benefit compared to the standard chemotherapy. In western countries, it has become a standard of care. Whereas in Japan, owing to the unapproval of G-CSF primary prophylactic administration, Dose-dense chemotherapy has not been defined for a long time in spite of its efficacy. Although in recent years, the number of reports regarding D-D therapy is slightly increasing in this country, prospective feasibility study is still uncommon. To verify of the feasibility of D-D chemotherapy, we conducted a multicenter phaseII study. Methods: We enrolled patients aged under 70years, with HER2 negative and operable node-positive primary breast cancer from 10centers. The primary end point was pCR rate, and the secondary end points were safety(FN rate, completion rate),overall response rate, toxicity profile and RDI. Neoadjuvant chemotherapy with D-D AC or EC followed by PTX was administrated to eligible patients every 2weeks with Pegfilgrastim support. 50 patients were scheduled to be enrolled. Results: 41/50 patients have been enrolled to this point. In analysis of 14/41 patients, median age was 48years(34-66), Histological subtypes were 57% Triple negative, 21% Luminal A Like, 21% LuminalB like. Clinical stageII and III were 64%, 36% respectively, and of them, StageIIIC was included at 21%. pCR rate showed 25% and, all were TN patients. Overall response rate was 100%, Grade3 or worse adverse events occurred in 33% of the patients (febrile neutropenia, pneumonia and so on). 20% of the patients were converted from q2w PTX to wPTX because of Grade3 adverse event. At the present, 80% accrual enrollment has been achieved. We plan to report the result of 50 patients full analysis. were assessed in both core needle biopsy performed prior to NAC and surgical samples. Results: The median age was 56.0 years and the mean tumor size was 3.38 cm. Clinical nodal status was positive in 60.7% of patients before NAC. ER, PgR and HER2 were positive in 72.6%, 58.9% and 28.0% of patients before NAC. Changes in ER, PgR and HER2 status between pre-and post-NAC were 9.6% (5.4% gain; 4.2% loss), 19.6% (6.5% gain; 13.1% loss) and 9.7% (3.0% gain; 6.7% loss), respectively. The median Ki67 level was significantly decreased after NAC (25.0% vs. 3.0%; P < 0.001). Patients with a loss in ER status after NAC tended towards a worse disease-free survival (DFS) compared with patients who maintained the ER positivity (14.7 vs. 37.9 months, P ¼ 0.188). Conversely, a loss in PgR status did not correlate with worse DFS (42.3 vs.42.5 months, P ¼ 0.494). HER2 loss group tended to have better DFS compared with the concordant HER2-positive group (60.9 vs. 25.4 months, P ¼ 0.362), and HER2 gain group tended to have worse DFS compared with the concordant HER2-negative group (24.7 vs. 36.9 months, P ¼ 0.265). Accordingly, HER2 loss showed the longest DFS, whereas HER2 gain showed the shortest DFS (60.9 vs. 24.7 months, P ¼ 0.032).
Purpose: The objective of this study is to evaluate the frequency of biomarker discordance after neoadjuvant chemotherapy (NAC) in patients with residual disease and their relationship with prognosis. Methods: From a prospective database of 225 patients receiving NAC from January 2005 to June 2016, 168 patients (74.7%) with non-pCR were analyzed. ER, PgR, HER2 and Ki67 were assessed in both core needle biopsy performed prior to NAC and surgical samples. Results: The median age was 56.0 years and the mean tumor size was 3.38 cm. Clinical nodal status was positive in 60.7% of patients before NAC. ER, PgR and HER2 were positive in 72.6%, 58.9% and 28.0% of patients before NAC. Changes in ER, PgR and HER2 status between pre-and post-NAC were 9.6% (5.4% gain; 4.2% loss), 19.6% (6.5% gain; 13.1% loss) and 9.7% (3.0% gain; 6.7% loss), respectively. The median Ki67 level was significantly decreased after NAC (25.0% vs. 3.0%; P < 0.001). Patients with a loss in ER status after NAC tended towards a worse disease-free survival (DFS) compared with patients who maintained the ER positivity (14.7 vs. 37.9 months, P ¼ 0.188). Conversely, a loss in PgR status did not correlate with worse DFS (42.3 vs.42.5 months, P ¼ 0.494). HER2 loss group tended to have better DFS compared with the concordant HER2-positive group (60.9 vs. 25.4 months, P ¼ 0.362), and HER2 gain group tended to have worse DFS compared with the concordant HER2-negative group (24.7 vs. 36.9 months, P ¼ 0.265). Accordingly, HER2 loss showed the longest DFS, whereas HER2 gain showed the shortest DFS (60.9 vs. 24.7 months, P ¼ 0.032). Although there was no correlation between pre-NAC Ki67 levels and DFS, patients with high (>20%) post-NAC Ki67 levels had significantly shorter DFS when compared with low (<20%) Ki67 levels (17.0 months vs. 20.2 months, P ¼ 0.017). Conclusion: These data suggested that biomarker status on residual disease after NAC might be helpful in selecting patients at different risk of relapse. Background: Neuroendocrine carcinoma (NEC) of the urinary tract is an uncommon tumor, and there is no standard approach to the management. Although some studies evaluated neoadjuvant chemotherapy, preoperative diagnosis of NEC is difficult due to tumor heterogeneity. Nevertheless, the reports of adjuvant chemotherapy (AC) were limited. Methods: We reviewed the medical records of patients with NEC of the urinary tract in our hospital between April 2010 and December 2016. The clinical courses and treatments were evaluated retrospectively.
Results: We identified 7 patients with NEC of the urinary tract who underwent radical resection. There were 6 males and 1 female, with a median age of 64 years (range, 62-77) . The primary tumor sites were bladder, ureter and renal pelvis (n ¼ 5/1/1). Preoperative histological diagnoses were NEC, NEC combined with urothelial carcinoma, and urothelial carcinoma (n ¼ 1/1/5). All patients were confirmed as stage III pathologically. The median estimated glomerular filtration rate before surgery and AC were 51.9 (range, 31.5-86.9) and 38.9 (range, 33.3-67.6) mL/min/1.73m 2 respectively. All patients were administered AC, which included carboplatin (CBDCA) and etoposide, cisplatin (CDDP) and etoposide, and CDDP and gemcitabine (n ¼ 4/2/1). On a median follow up of 19.5 months, 3 recurred (local/lymph node/distant; 0/2/2, overlapping data) and they all died due to disease progression (relapse-free survival; 4.0/7.0/ 10.1 months, and overall survival; 4.3/16.7/18.9 months). Of 4 patients treated with CBDCA-based regimen, 3 relapsed, whereas of 3 with CDDP-based regimen, none relapsed. The treatment-related adverse events of grade 3 or 4 were as follows: neutropenia, thrombocytopenia, and infection (n ¼ 6/2/1). Six patients required treatments delay or dose reduction. Conclusions: Despite the use of AC, the outcome of urothelial NEC patients remains poor. Further investigations are warranted. Result: male/female 14/11, median age 64(33-77),primary site was pancreas/intestine 13/12, previous treatment presence 14(56%). Administration method was weekly/daily 14/11. Overall RR 36% (9/25), DCR 60% (15/25). MGMT expression;positive/negative were 15/14. Response cases of MGMT negative group were 6/10(60%) and non-response cases (SDþPD)of MGMT positive group were 93.3%(14/15), accuracy was 80.0%(20/22). There were significant relations for MGMT expression and effect of treatment of STZ (P ¼ 0.003). Sub-analysis by primary site, pNET were good(P ¼ 0.013)(the sensitivity, specificity, accuracy were 83.3%, 85.7%, 84.6%, respectively),while the accuracy of GI-NET remained 75%(P ¼ 0.139). Conclusions: MGMT expression and effect of treatment of STZ have a strong correlation especially for pNET and hold the promising possibility as treatment predictive biomarker.
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Background: Somatostatin receptor scintigraphy (SRS) has been widely used for diagnosis and treatment of neuroendocrine neoplasm (NEN) for 20 years worldwide. SRS has been approved for clinical use under public health insurance from January 2016 in Japan. Method: We retrospectively reviewed medical records of patients who received SRS from January 2016 to January 2017. Result: Eight patients (4 male and 4 female) received SRS, and the median age was 56 years old (37-72). Of whom, five patients were diagnosed as NEN, including one functioning pancreatic and duodenal NEN of multiple endocrine neoplasia type 1. Remaining four were non-functioning NEN, originated from rectum (one patient with WHO classification grade 2) and pancreas (2 with grade 2 and 1 with grade 3). Positive uptake in SRS was detected in all NEN patients except for one patient with grade 3. SRS revealed that the primary tumor site was rectum in a patient with severe liver involvement. Two patients with pancreatic NEN were treated with somatostatin analogue according to positive results of SRS and obtained good disease control. Three patients later diagnosed as non-NEN showed negative uptake in SRS. Discussion: As reported so far, well-differentiated NEN was positive for SRS. SRS was useful to determine whether somatostatin analogue should be administered or not, and to explore a location of primary lesion. Conclusion: SRS should be considered for well differentiated NEN.
